DalCor is a biopharmaceutical company with a focus on addressing cardiovascular disease, the greatest global healthcare burden. Our purpose is to deliver the first pharmacogenomic precision medicine in cardiovascular disease that specifically targets patients with the ADCY9 AA genotype. The company has operations in Canada, the UK, Switzerland, and the U.S. dal-GenE Phase 3 Clinical Trial DalCor is conducting dal-GenE (DAL-301), the first interventional precision medicine cardiovascular outcomes trial. This Phase 3 clinical trial is evaluating the efficacy of dalcetrapib versus placebo to reduce clinical cardiovascular events in 6,149 patients who have experienced an -Acute Coronary Syndrome (ACS) who carry the ADCY9 rs1967309 AA genotype. The trial aims to reduce major adverse cardiovascular events (MACE). The dal-GenE trial is fully recruited, passed a futility analysis in January 2020, and trial completion is expected in the first half of 2021. dal-COVID Clinical Trial Coronavirus disease 2019 (COVID-19) is defined as illness caused by a novel coronavirus now called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Pre-clinical research has identified that the main protease (3CLMpro) of the SARS-CoV-2 virus is a key enzyme that plays a pivotal role in mediating viral replication and transcription. Dalcetrapib is a potential anti-viral treatment as it binds to the catalytic site of 3CLMpro of SARS-CoV-2 in vitro, thereby inhibiting its activity and viral replication. In December 2020, DalCor initiated the dal-COVID trial, a Phase 2 proof-of-concept study for dalcetrapib as a potential oral anti-viral treatment for COVID-19. dal-COVID is a double-blind, placebo-controlled trial in patients with confirmed mild to moderate symptomatic COVID-19. The study will evaluate the efficacy and safety of three different doses of dalcetrapib compared to placebo in approximately 200 adult patients over a 10-day treatment period. Results are anticipated in Q1 2021